Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nasonex, Flonase Detail Aids Make Unproven Superiority Claims - DDMAC Letter

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA asks Schering-Plough, GlaxoSmithKline to pull detail material containing “unsubstantiated,” and “false and misleading” claims.

You may also be interested in...



GSK’s Veramyst To Launch By Late May

Flonase follow-on is indicated for treatment of seasonal and perennial allergic rhinitis in adults and children two years of age and older.

GSK Drops Suit Against FDA Approval Of Generic Flonase

Par and Roxane resume shipment of generic fluticasone following the expiration of a temporary restraining order.

Solvay's Androgel REMS Proposal May Need More Restrictions - Cmte.

Solvay may need a more restrictive Risk Evaluation and Mitigation Strategy for AndroGel 1% to adequately warn against the danger of secondary transfer of the testosterone gel, according to some members of FDA's Pediatric Advisory Committee

Topics

UsernamePublicRestriction

Register

OM013658

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel